A review of possible therapeutic agents for COVID-19 pandemic
Publication Type
Subject review
Authors
Fulltext
Download

The epidemic of Coronavirus disease 2019 (COVID-19) caused by novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome, coronavirus 2) infection has been considered by the World Health Organization (WHO) as a public health emergency of global interest. The efforts nowadays of different countries focus on the fast isolation and fast diagnosis of patients as well as to find possible therapeutic agent or vaccine. Several sites, articles, reports, reviews, and web pages discussing COVID-19 virus and possible treatments were investigated, the data were collected be-tween November-2020 and May-2021. Approximately 170 articles and reports were opened and read, but nearly 80 of them were used for this review. Several drugs showed hopeful potential re-sults such as colchicine, dexamethasone, kaletra (Lopinavir/ritonavir), cefuroxime, favipiravir, and inhaled furosemide, but until now there is no WHO approved antiviral drug against COVID-19, although remdesivir is approved by Food and drug administration (FDA) as antiviral for COVID-19, but WHO doesn’t recommend it’s use. The protocol followed by WHO until now is a sympto-matic treatment, e.g., antipyretics, antitussive, adequate nutrition, and rehydration, antibiotics if suffering from secondary infection, antithrombotic prophylaxis for hospitalized COVID-19 pa-tients, and corticosteroids in exacerbation cases. Fortunately, there are several vaccines that reached an advanced phase in research trials, and the world is hopeful for mass vaccination in early to mid-2021. Currently, there is no WHO-approved treatment for COVID-19, but there are many other promising drugs/agents under investigation. Supportive care and protocols were followed to manage the current crisis situation. However, many vaccines are approved for the prevention of COVID-19 available now such as Vaxzevria (Astrazeneca vaccine), tozinameran (Pfizer/BioNTech vaccine), Moderna: mRNA-1273 vaccine and Janssen COVID-19 vaccine while others are still in clinical trials.

Journal
Title
Palestinian Medical and Pharmaceutical Journal
Publisher
Palestinian Medical and Pharmaceutical Journal
Publisher Country
Palestine
Indexing
Scopus
Impact Factor
None
Publication Type
Prtinted only
Volume
7
Year
2022
Pages
--